Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

OUTLOOK THERAPEUTICS INC

Healthcare US OTLK

1.22USD
0.12(10.91%)

Last update at 2026-06-12T20:29:00Z

Day Range

1.121.31
LowHigh

52 Week Range

4.0040.60
LowHigh

Fundamentals

  • Previous Close 1.10
  • Market Cap185.72M
  • Volume37378560
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-59.78472M
  • Revenue TTM5.85M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM -42.33086M
  • Diluted EPS TTM-11.96

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -58.98000M -66.04946M -53.16100M -38.51100M -37.93479M
Minority interest - - - - -
Net income -58.98300M -66.05226M -53.16300M -35.23900M -34.52379M
Selling general administrative 26.67M 20.74M 12.77M 9.97M 9.37M
Selling and marketing expenses - - - - -
Gross profit - - - -527624.00000M -11270101.85388M
Reconciled depreciation 0.04M 0.20M 0.26M 0.55M 3.36M
Ebit -52.64319M -63.07075M -51.72700M -36.84100M -36.29906M
Ebitda -52.59900M -62.91479M -51.77300M -36.31300M -21.66708M
Depreciation and amortization 0.04M 0.16M -0.04600M 0.53M 14.63M
Non operating income net other - -0.60835M -0.49849M -1.71133M 1.83M
Operating income -53.12600M -63.07075M -51.72700M -36.84100M -36.29906M
Other operating expenses 53.13M 63.07M 51.73M 36.31M 33.18M
Interest expense 1.56M 1.49M 0.94M 1.76M 3.47M
Tax provision 0.00300M 0.00280M 0.00200M -3.27196M -3.41100M
Interest income - - - - 3.47M
Net interest income -1.56000M -1.48746M -0.93613M -1.75647M -3.46669M
Extraordinary items - - - - -
Non recurring - - - 0.53M 11.27M
Other items - - - - -
Income tax expense 0.00300M 0.00280M 0.00200M -3.27200M -3.41100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 8.15M
Total operating expenses 53.13M 63.07M 51.73M 36.31M 33.18M
Cost of revenue - - - 527624.00M 11270110.00M
Total other income expense net -4.29400M -2.97871M -1.43400M -1.67000M -1.63573M
Discontinued operations - - - - -
Net income from continuing ops -58.98300M -66.05226M -53.16335M -35.23950M -34.52379M
Net income applicable to common shares - -66.05226M -53.16335M -48.87376M -36.03967M
Preferred stock and other adjustments - - - 0.17M 0.62M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 32.30M 28.53M 22.81M 19.73M 17.13M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7.59M 10.12M 7030823.00M 5407882.00M 5486033.00M
Total liab 46.74M 19.79M 18.20M 16.91M 27.90M
Total stockholder equity -14.43800M 8.74M 4.61M 2.83M -10.76996M
Deferred long term liab - 0.12M - - -
Other current liab -1856624.39779M 5.28M 3.58M 5.64M 6.48M
Common stock 2.60M 2.27M 1.76M 1.27M 0.29M
Capital stock 2.60M 2.27M 1.76M 1.27M 5.65M
Retained earnings -467.91819M -408.93552M -342.88325M -289.71991M -254.48041M
Other liab - 0.06M 0.52M 0.07M 4.20M
Good will - - - - -
Other assets 0.00040M 0.13M -0.00045M 0.00045M 0.46M
Cash 23.39M 17.40M 14.48M 12.54M 8.02M
Cash and equivalents - - - - -
Total current liabilities 46.73M 19.73M 6.75M 15.89M 20.29M
Current deferred revenue 1856629.00M - - - -
Net debt 12.16M -6.43878M -2.57462M -3.73814M 6.93M
Short term debt 35.56M 10.95M 0.97M 7.85M 11.53M
Short long term debt 35.55M 10.92M 0.90M 3.66M 11.34M
Short long term debt total 35.56M 10.96M 11.90M 8.80M 14.95M
Other stockholder equity 450.88M -28527335.60102M 345.73M 291.27M 238.06M
Property plant equipment - 0.07M 0.16M 0.33M 3.18M
Total current assets 30.98M 27.52M 21.51M 17.94M 13.50M
Long term investments 0.79M 0.80M 0.85M - -
Net tangible assets - 8.74M 4.61M 2.83M -16.12936M
Short term investments - - - - -
Net receivables - - 0.10M 0.80M 1.20M
Long term debt - - 10.89M 0.90M 0.05M
Inventory - - - - -
Accounts payable 6.57M 3.49M 2.20M 2.39M 2.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -32300601.00000M - -22811451.00000M -19732551.00000M -1.05148M
Additional paid in capital - - - - -
Common stock total equity - 2.27M 1.76M 1.27M 0.29M
Preferred stock total equity - - - - -
Retained earnings total equity - -408.93552M -342.88325M -289.70000M -254.48041M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.50M 0.13M 0.17M 1.29M 0.46M
Deferred long term asset charges - - - - -
Non current assets total 1.32M 1.01M 1.30M 1.79M 3.63M
Capital lease obligations 0.00427M 0.04M 0.11M 4.23M 3.56M
Long term debt total - - 10.89M 0.90M 3.42M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments - - 0.00000M -0.90000M -0.43731M
Change to liabilities - 1.45M -5.49763M -0.71065M -9.86255M
Total cashflows from investing activities - - - -0.90000M -0.43731M
Net borrowings - -2.89265M 6.33M 0.86M -6.94374M
Total cash from financing activities 48.97M 59.59M 56.19M 37.21M 39.03M
Change to operating activities - -2.97952M -6.88093M 0.22M -3.72042M
Net income -58.98267M -66.05226M -53.16335M -35.23950M -34.52379M
Change in cash 6.00M 2.92M 1.94M 4.52M 6.30M
Begin period cash flow 17.40M 14.48M 12.54M 8.02M 1.72M
End period cash flow 23.39M 17.40M 14.48M 12.54M 8.02M
Total cash from operating activities -42.97340M -56.67456M -54.25329M -31.79009M -32.28999M
Issuance of capital stock 30.02M 62.31M 46.30M 35.43M 45.96M
Depreciation 0.04M 0.20M 0.26M 0.55M 3.36M
Other cashflows from investing activities - - - - -
Dividends paid - - - 166133.00M 624988.00M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 62.51M 49.90M 166133.00M 624988.00M
Other cashflows from financing activities 29.18M 9.61M 13.59M 2.04M 0.00435M
Change to netincome - 9.97M 6.28M 5.28M 12.07M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.44M
Change receivables - - - - -
Cash flows other operating - -2.25276M -2.13411M -1.67604M -3.33233M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 2.92M 1.94M 4.52M 6.30M
Change in working capital 4.75M -1.68439M -7.07940M -1.26972M -13.19488M
Stock based compensation 5.55M 7.71M 4.89M 2.81M 1.31M
Other non cash items 5.66M 3.15M 0.34M -0.88133M 1.31M
Free cash flow -42.97340M -56.67456M -54.25329M -31.79009M -32.72729M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OTLK
OUTLOOK THERAPEUTICS INC		 0.12 10.91% 1.22 - 2.85 13.27 10.19 23.71 -4.1278
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OUTLOOK THERAPEUTICS INC

Building F, Iselin, NJ, United States, 08852

Key Executives

Name Title Year Born
Mr. Ralph H. Thurman Independent Exec. Chairman 1949
Mr. C. Russell Trenary III Pres, CEO & Director 1958
Mr. Lawrence A. Kenyon CPA Exec. VP, CFO, Treasurer, Company Sec. & Director 1966
Mr. Terry Dagnon Chief Operations Officer 1962
Mr. Jeffrey Evanson Chief Commercial Officer 1969
Rick Gregory Director of Marketing & Communications NA
Ms. Alicia Tozier Sr. VP, Marketing & Market Access NA
Mr. Joel Prieve Sr. VP of Commercial Operations NA
Dr. Balu N. Balasubramanian Ph.D. Advisor NA
Ms. Elizabeth A. Yamashita Advisor 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.